ICCM

ICCM

Icecure Medical

Net -4.56%top 1%Rev 5.50%top 1%Revenue grew 100% of years1Y
Hold

IceCure Medical develops and markets cryoablation systems for tumor treatment, including the ProSense and IceSense3 systems. These technologies target malignant tumors across various medical fields, serving hospitals and clinics globally.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 10 years ago โ†’$15,533today

Score Overview

1 Year
Scoreโ€”
Net Growth-4.56%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth5.50%
Rev TrendGrew
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-56.40%
Net Trend40%
Net Income Consistency
Rev Growth-13.85%
Rev Trend80%
Revenue Consistency

See the full market ranking โ†’

Icecure Medical fundamental performance

Across Icecure Medical's full reported history, from 2021 to 2025, revenue declined from $ 4M to $ 3M and net income went from -$ 10M to -$ 15M. Revenue increased in 80% of the years measured; net income in 40%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 3.10โ€”
1 Year2025-08-12
$ 24.60-87.38%
5 Years2021-08-12
$ 0.01248x
10 Years2016-01-11
$ 0.2015x
All Time2021-08-26
$ 327.00-99.05%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 3M-$ 15M$ 8M
2025$ 3M-$ 15M$ 8M
2024$ 3M-$ 15M$ 7M
2023$ 3M-$ 14M$ 11M
2022$ 3M-$ 17M$ 23M
IPO2021$ 4M-$ 10M$ 25M

Explore beyond ICCM

You're looking at Icecure Medical. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies